Find, compare & contact
Raloxifenum (Raloxifene)
API Manufacturers & Suppliers
Switzerland
Peru
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Follow us
Producer
Produced in:
Established in: 2021
MOQ: -
Employees: 19
API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides
Small quantity APIs to commercial scale
GMP and USFDA certification based on quantity, order, assignment.
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
Produced in:
Established in: 1984
MOQ: -
Employees: 21,650
Diverse portfolio of 180+APIs
1754+ DMF across global markets
1100+ patents filed, and more than 70 own patents granted
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
Produced in:
Established in: 1944
MOQ: -
Employees: 4,000
14 international API plant sites
Portfolio of 350+ APIs
Teva is among the world’s largest generic drug/API manufacturers
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Raloxifene API 84449-90-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Raloxifene. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Raloxifene
- Synonyms:
- Keoxifene , LY 139481 , RAL , Raloxifene , Raloxifeno , Raloxifenum , Raloxifene hydrochloride
- Cas Number:
- 84449-90-1
- DrugBank number:
- DB00481
- Unique Ingredient Identifier:
- YX9162EO3I
About Raloxifene
What makes Raloxifene unique? Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself. The most common causes of osteoporosis include postmenopausal deficiency of estrogen and age-related deterioration in bone homeostasis.
Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent therapies is critical. Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and tamoxifen have been developed to reduce adverse events through selective pharmacological actions on tissue-specific therapeutic targets. The main effects of raloxifene are to preserve the bone mineral density and decrease the risk of breast cancer in postmenopausal women. Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation.
You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.
Raloxifene is a type of Estrogens
Estrogens are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in hormone therapy and women's health. Estrogens are a class of steroidal compounds that are primarily produced in the ovaries and play a significant role in the development and maintenance of female reproductive tissues and secondary sexual characteristics. These APIs are widely used in various pharmaceutical formulations, including oral contraceptives, hormone replacement therapies, and treatments for menopausal symptoms. They are also utilized in the management of conditions such as hypogonadism, infertility, and certain types of cancer.
Estrogens exert their effects by binding to estrogen receptors, which are present in various tissues throughout the body. This binding initiates a cascade of cellular and molecular events that regulate gene expression and modulate physiological processes.
Some common examples of estrogens used in pharmaceutical formulations include estradiol, estrone, and estriol. These compounds are typically synthesized from natural sources or derived from plant-based substances through a series of chemical reactions and purification processes.
As with any pharmaceutical API, the production of estrogens follows strict quality control guidelines to ensure purity, potency, and safety. Stringent regulatory standards and rigorous testing protocols are employed to guarantee consistent quality and adherence to pharmaceutical industry regulations.
In conclusion, estrogens are a vital subcategory of pharmaceutical APIs with a wide range of applications in women's health and hormone therapy. Their role in maintaining hormonal balance and addressing various medical conditions underscores their importance in modern medicine.
Raloxifene (Estrogens), classified under Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
Raloxifene manufacturers | traders | suppliers
We have 13 companies offering Raloxifene produced in 4 different countries.
Get in contact with the supplier of your choice:
- SETV Global from India, product country of origin India
- Hanmi Fine Chemical from South Korea, product country of origin South Korea
- Cambrex from Italy, product country of origin Unknown
- Dr. Reddy's from India, product country of origin India
- Apotex Pharmachem from India, product country of origin India
- Sai-Tech Pharmaceuticals Pvt. Ltd. from India, product country of origin India
- Torrent Pharma from India, product country of origin India
- Raks Pharma from India, product country of origin India
- Teva API from Israel, product country of origin Unknown
- Glochem from India, product country of origin India
- Hetero Drugs from India, product country of origin Unknown
- Cipla from India, product country of origin India
- Erregierre from Italy, product country of origin Italy
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
